Verana Health and Janssen Research & Development have entered into a collaboration to transform ophthalmology and urology real-world data (RWD) into organized, actionable datasets to inform clinical study design and enhance the execution of clinical trials.
In ophthalmology, Janssen’s goal is to develop new ophthalmic therapies and treatments for patients with diabetic macular edema (DME), a complication of diabetes that may lead to severe vision loss for the 750,000 people in the United States with the disease. Using real-world data from the American Academy of Ophthalmology (AAO) Intelligent Research in Sight Registry (IRIS® Registry), Verana Health will help to characterize baseline patient attributes, disease progression, and treatment-based outcomes — research which is currently limited in this population.
In urology, the focus will be on characterizing outcomes for patients with early-stage prostate cancer — research which is currently lacking across most oncology databases. Janssen and Verana Health will collaborate on a pilot program to curate and evaluate de-identified data from the American Urological Association Quality (AQUA) Registry.
The impact this research could have on the lives of so many men and women is significant. With partnerships in Life Science — like this collaboration with Janssen — Verana Health is able to further advance the utilization of real-world evidence (RWE) and specialized data science to accelerate clinical research and development, all in service of improving patient outcomes.
Read more about the Verana Health collaboration with Janssen here.